First Time Loading...

Exelixis Inc
NASDAQ:EXEL

Watchlist Manager
Exelixis Inc Logo
Exelixis Inc
NASDAQ:EXEL
Watchlist
Price: 23.7 USD 0.72% Market Closed
Updated: Apr 29, 2024

Exelixis Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exelixis Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Exelixis Inc
NASDAQ:EXEL
Operating Income
$170.9m
CAGR 3-Years
16%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Exelixis Inc's Operating Income?
Operating Income
170.9m USD

Based on the financial report for Dec 29, 2023, Exelixis Inc's Operating Income amounts to 170.9m USD.

What is Exelixis Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-17%

Over the last year, the Operating Income growth was -15%. The average annual Operating Income growth rates for Exelixis Inc have been 16% over the past three years , -17% over the past five years .